Okomistin eye, ear, nasal drops 0.01% bottle 10 ml in Moscow

The drug is more effective against gram-positive bacteria, including: staphylococci, streptococci. It has an antifungal effect on ascomycetes of the genus Aspergillus and the genus Penicillium, yeasts (Rhodotorula tubra, Torulopsis glabrata) and yeasts (Trichophyton rubrum, Trichophyton mentagrophytes, Trichophyton verrucosum, T. schoenleini, T. violaceum, Epidermophyton Kaufman-Wolf, E, floccosum, Microsporum gypseum , Microsporum canis), as well as other pathogenic fungi (for example, Pityrosporum orbiculare (Malassezia furfur)) in the form of monocultures and microbial associations, including fungal microflora with resistance to chemotherapeutic drugs.

The action of benzyldimethyl-myristoylamino-propylammonium is based on the direct hydrophobic interaction of the molecule with the lipids of the membranes of microorganisms, leading to their fragmentation and destruction.
In this case, part of the benzyldimethylmyristoylaminopropylammonium molecule, plunging into the hydrophobic portion of the membrane, destroys the supra-membrane layer, loosens the membrane, increases its permeability to large molecular substances, changes the enzymatic activity of the microbial cell, inhibits enzyme systems, which leads to inhibition of the vital activity of microorganisms and their cytolysis. Benzyldimethyl-myristoylamino-propylammonium has a high selectivity of action against microorganisms, because has virtually no effect on the membranes of human cells, which is due to the different structure of the latter - the significantly longer length of lipid radicals, which sharply limits the possibility of hydrophobic interaction of benzyldimethyl-myristoylamino-propylammonium with cells. Under the influence of the drug, the resistance of bacteria and fungi to antibiotics is reduced. Benzyldimethyl-myristoylamino-propylammonium has anti-inflammatory and immunoadjuvant effects, enhances local protective reactions, regenerative processes, activates nonspecific defense mechanisms due to modulation of the cellular and local humoral immune response.

Okomistin® (Okomistin®)

It has an antifungal effect on ascomycetes of the genus Aspergillus and the genus Penicillium, yeasts (Rhodotorula tubra, Torulopsis glabrata) and yeasts (Trichophyton rubrum, Trichophyton mentagrophytes, Trichophyton verrucosum, T. schoenleini, T. violaceum, Epidermophyton Kaufman-Wolf, E, floccosum, Microsporum gypseum , Microsporum canis), as well as other pathogenic fungi (for example, Pityrosporum orbiculare (Malassezia furfur)) in the form of monocultures and microbial associations, including fungal microflora with resistance to chemotherapeutic drugs.

The action of benzyldimethyl-myristoylamino-propylammonium is based on the direct hydrophobic interaction of the molecule with the lipids of the membranes of microorganisms, leading to their fragmentation and destruction. In this case, part of the benzyldimethylmyristoylaminopropylammonium molecule, plunging into the hydrophobic portion of the membrane, destroys the supra-membrane layer, loosens the membrane, increases its permeability for large molecular substances, changes the enzymatic activity of the microbial cell, inhibits enzyme systems, which leads to inhibition of the vital activity of microorganisms and their cytolysis. Benzyldimethyl-myristoylamino-propylammonium has a high selectivity of action against microorganisms, because has virtually no effect on the membranes of human cells, which is due to the different structure of the latter - the significantly longer length of lipid radicals, which sharply limits the possibility of hydrophobic interaction of benzyldimethyl-myristoylamino-propylammonium with cells.

Under the influence of the drug, the resistance of bacteria and fungi to antibiotics is reduced. Benzyldimethyl-myristoylamino-propylammonium has anti-inflammatory and immunoadjuvant effects, enhances local protective reactions, regenerative processes, activates nonspecific defense mechanisms due to modulation of the cellular and local humoral immune response.

Okomistin eye drops 0.01% fl-cap 10ml

Compound

Active substance: benzyldimethyl[3-(myristoylamino)propyl] ammonium chloride monohydrate (in terms of anhydrous substance) - 0.01 g. Excipients: sodium chloride - 0.9 g, purified water - up to 100 ml.

Pharmacokinetics

The drug has a local effect. There are no data on possible penetration into the bloodstream.

Indications for use

Ophthalmology:

in the complex treatment of infectious processes in the anterior part of the eye (blepharitis, conjunctivitis, keratitis, keratouveitis), eye injuries, eye burns (thermal and chemical);
in the preoperative and postoperative periods for the treatment and prevention of purulent-inflammatory eye lesions;
prevention of ophthalmia in newborns, incl. gonococcal and chlamydial.

Otorhinolaryngology:

in the complex treatment of acute sinusitis/rhinosinusitis, exacerbation of chronic sinusitis/rhinosinusitis, acute rhinitis;
in the complex treatment of acute and chronic external otitis, chronic purulent mesotympanitis, otomycosis.

Contraindications

Individual sensitivity to the components of the drug.

Directions for use and doses

The drug is used topically.

Ophthalmology

For therapeutic purposes in adults, Okomistin® is instilled into the conjunctival sac, 1-2 drops 4-6 times a day until clinical recovery.
For prophylactic purposes, the drug is instilled 2-3 days before surgery, as well as for 10-15 days after surgery, 1-2 drops 3 times a day.
When treating eye burns, after washing the eye with plenty of water, frequent instillations are carried out (every 5-10 minutes) for 1-2 hours. For further treatment, the drug is used 1-2 drops 4-6 times a day.
For the treatment of bacterial conjunctivitis in children, Okomistin® is instilled into the conjunctival sac, 1 drop up to 6 times a day for 7-10 days.
To prevent ophthalmia in newborns, immediately after birth, the child is instilled with 1 drop of the drug into each eye 2 times with an interval of 2-3 minutes.

Otorhinolaryngology

For acute sinusitis/rhinosinusitis, exacerbation of chronic sinusitis/rhinosinusitis, acute rhinitis, infection of the nasal mucosa for adults, Okomistin® is instilled 2-3 drops into each nostril 4-6 times a day. The course of treatment is up to 14 days.
For the treatment of acute rhinosinusitis, exacerbation of chronic rhinosinusitis in children over 1 year of age, Okomistin® is instilled into each nasal passage, 1-2 drops up to 4-6 times a day for 10-14 days.
For acute and chronic external otitis and otomycosis in adults, Okomistin® is instilled into the external auditory canal 5 drops 4 times a day, or instead of instillation, a gauze turunda soaked in the drug is instilled into the external auditory canal 4 times a day. The course of treatment is 10 days.
For chronic mesotympanitis, the drug is used in adults in complex treatment using hardware ultrasonic irrigation or injection into the tympanic cavity together with antibiotics.
In the absence of positive dynamics (increased severity or appearance of new signs/symptoms of the disease, the occurrence of complications) on the 3-4th day of therapy using the drug Okomistin®, the patient should consult a doctor.

Storage conditions

The drug should be stored out of the reach of children at a temperature not exceeding 25°C.

Best before date

3 years.
Do not use after expiration date. Shelf life after opening the bottle is 1 month.

special instructions

Contact lenses should be removed immediately before instillation of Okomistin® and installed no earlier than 15 minutes after instillation.

To avoid contamination and cross-infection, do not use the same vial to treat eye, nose, and/or ear infections at the same time. To prevent contamination of the solution when instilling the drug, patients should avoid contact of the dropper tip with the eye and skin. Sharing a dropper bottle by more than one person may spread the infection.

Use in pediatrics

The drug can be used in pediatric practice.

Description

Antiseptic for local use.

Dosage form

Eye, ear, nasal drops in the form of a colorless, transparent liquid.

Use in children

The drug can be used in pediatric practice.

Pharmacodynamics

The main active ingredient of the drug Okomistin® is the antiseptic benzyldimethyl-myristoylamino-propylammonium, which has a pronounced antimicrobial effect against gram-positive and gram-negative, aerobic and anaerobic bacteria in the form of monocultures and microbial associations, including hospital strains with multidrug resistance to antibiotics. The drug acts on chlamydia, pathogenic fungi, as well as herpes viruses and adenoviruses. The drug is more effective against gram-positive bacteria, incl. staphylococci, streptococci. It has an antifungal effect on ascomycetes of the genus Aspergillus and the genus Penicillium, yeasts (Rhodotorula rubra, Torulopsis glabrata) and yeasts (Trichophyton rubrum, Trichophyton mentagrophytes, Trichophyton verrucosum, Trichophyton schoenleini, Trichophyton violaceum, Epidermophyton Kaufmann-Wolf, Epidermophyton floccos um, Microsporum gypseum, Microsporum canis ), as well as other pathogenic fungi (for example, Pityrosporum orbiculare (Malassezia furfur)) in the form of monocultures and microbial associations, including fungal microflora with resistance to chemotherapeutic drugs.

Benzyldimethyl-myristoylamino-propylammonium has a high selectivity of action against microorganisms, because has virtually no effect on the membranes of human cells, which is due to the different structure of the latter - the significantly longer length of lipid radicals, which sharply limits the possibility of hydrophobic interaction of benzyldimethyl-myristoylamino-propylammonium with cells.

Side effects

Possible: allergic reactions.

In some cases: a slight burning sensation, discomfort, which goes away on its own after 15-20 seconds and does not require discontinuation of the drug.

If any adverse events occur, the patient should consult a doctor

Use during pregnancy and breastfeeding

The use of the drug during pregnancy and breastfeeding is possible only if the expected benefit to the mother outweighs the potential risk to the fetus and child.

Interaction

When used together, Okomistin® increases the effectiveness of topical antibiotics.

Interaction studies of the drug with other drugs have not been conducted.

Overdose

Not observed.

Impact on the ability to drive vehicles and operate machinery

After using the drug, a temporary decrease in the clarity of visual perception is possible, therefore, until it is restored, it is not recommended to drive a car or engage in activities that require increased attention and reaction.